
Abbott Laboratories company profile
$108.52+1.18%Close 13 Nov 2026 · Market value $187.6B
About Abbott Laboratories
Abbott Laboratories is an Illinois corporation engaged in the discovery, development, manufacture, and sale of a broad line of healthcare products. Its operations are organized into established pharmaceutical products, diagnostic products, nutritional products, and medical devices. The established pharmaceutical segment includes branded generic pharmaceuticals, largely marketed outside the United States in emerging markets, and sells to wholesalers, distributors, government agencies, healthcare facilities, and pharmacies. The diagnostic segment sells laboratory, point-of-care, and rapid diagnostic systems and tests to blood banks, hospitals, commercial laboratories, and clinics. The nutritional segment offers infant formula, adult and pediatric nutritional products, and enteral feeding products to consumers and institutions. The medical devices segment provides cardiovascular, diabetes care, and neuromodulation products to hospitals, physicians, and consumers. Abbott operates worldwide and has employees in more than 160 countries.
A summary of the business section of the company's latest annual report, filed 20 Feb 2026.
Company facts
| Ticker | ABT · NYSE |
|---|
| Sector | Pharmaceuticals |
|---|
| Industry | Health Care Equipment |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1800 |
|---|
| Latest annual report | 10-K, filed 20 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| D. J. Starks | Director | 6.7M | Open-market purchase, 27 Apr 2026 |
|---|
| H. L. Allen | EXECUTIVE VICE PRESIDENT, GC | 192K | Shares withheld for tax, 28 Feb 2025 |
|---|
| L. D. Earnhardt | EVP AND GROUP PRESIDENT | 71.9K | Shares withheld for tax, 27 Feb 2026 |
|---|
| C. J. Scoggins | EXECUTIVE VICE PRESIDENT | 63.6K | Shares withheld for tax, 27 Feb 2026 |
|---|
| P. P. Boudreau | EVP AND CFO | 51.0K | Shares withheld for tax, 1 Sep 2026 |
|---|
| R. J. Alpern | Director | 40.8K | Grant or award, 25 Apr 2025 |
|---|
| N. McKinstry | Director | 38.7K | Grant or award, 24 Apr 2026 |
|---|
| S. E. Blount | Director | 34.1K | Grant or award, 24 Apr 2026 |
|---|
| J. G. Stratton | Director | 19.0K | Open-market purchase, 7 May 2026 |
|---|
| M. A. Kumbier | Director | 15.7K | Grant or award, 24 Apr 2026 |
|---|
| D. W. McDew | Director | 10.4K | Grant or award, 24 Apr 2026 |
|---|
| M. F. Roman | Director | 8.5K | Grant or award, 24 Apr 2026 |
|---|
| C. Babineaux-Fontenot | Director | 5.3K | Grant or award, 24 Apr 2026 |
|---|
| M. G. O'Grady | Director | 5.3K | Grant or award, 24 Apr 2026 |
|---|
| Moreland Mary K | EXECUTIVE VICE PRESIDENT | — | Open-market sale, 5 Nov 2026 |
|---|
| Conroy Kevin T | Director | — | Shares withheld for tax, 23 Sep 2026 |
|---|
| MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | — | Open-market sale, 2 Sep 2026 |
|---|
| Ford Robert B | CHAIRMAN AND CEO · Director | — | Option exercise, 25 Aug 2026 |
|---|
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT | — | Code I, 12 Aug 2026 |
|---|
| Cushman Elizabeth C. | EVP, GC AND SECRETARY | — | Shares withheld for tax, 27 Jun 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
ABT in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.